ライフサイエンスコーパス: positron emission tomography

1 onary flow reserve (CFR) was determined from positron emission tomography.

2 ic resonance imaging, and fluorodeoxyglucose-positron emission tomography.

3 h glucose and palmitate tracer infusions and positron emission tomography.

4 al symptom severity in the past month before positron emission tomography.

5 ological evaluation and in vivo studies with positron emission tomography.

6 tery disease underwent serial (18)F-fluoride positron emission tomography.

7 users (8 females), using (11)C-nicotine and positron emission tomography.

8 and MVO(2) were evaluated using 11C-acetate positron emission tomography.

9 althy males and measured brain activity with positron emission tomography.

10 ent FDG-positron-emission tomography and NaF-positron-emission tomography.

11 penumbra detection against full quantitative positron emission tomography ((15) O-PET), the gold stan

12 erved clinically by (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET).

13 scaffold was studied as a template for (18)F-positron emission tomography ((18)F-PET) radiotracer dev

14 eceptor densities by using [(18)F]flumazenil positron emission tomography ([(18)F]FMZ-PET) and GABA c

15 and 6 mo was measured with 18sodium fluoride positron emission tomography (18F-NaF PET) scans as targ

16 2-Deoxy-2-[18F]fluoro-D-glucose (2-FDG) with positron emission tomography (2-FDG-PET) is undeniably u

17 hology measured in cerebrospinal fluid or by positron emission tomography(23).

18 (18)F-fluorodeoxyglucose positron emission tomography allows for near-universal c

19 Using positron emission tomography and [(18)F]FPEB, we quantif

20 We used [(11)C]FLB 457 positron emission tomography and amphetamine to measure

21 ts for AD] cohort) underwent amyloid and tau positron emission tomography and answered several questi

22 mer Network) study group cohort with amyloid positron emission tomography and behavioral data.

23 on an APOE4 or APOE3 genetic background, by positron emission tomography and by gamma counter.

24 dictions of brain Abeta burden quantified by positron emission tomography and CSF concentrations of A

25 ent rest and vasodilator stress N-13 ammonia positron emission tomography and echocardiography.

26 Brain fluorodeoxyglucose positron emission tomography and information on core fea

27 elopmental advances in imaging tools such as positron emission tomography and magnetic resonance imag

28 Positron emission tomography and microsphere MBF measure

29 Furthermore, the recent advent of tau positron emission tomography and novel fluid-based bioma

30 ethods to measure myocardial blood flow with positron emission tomography and single-photon emission

31 raphy and nuclear imaging techniques such as positron emission tomography and white blood cell scinti

32 ake were assessed by means of static 18F-FDG positron-emission tomography and computed tomography sca

33 eral carotid stenosis of >=50% underwent FDG-positron-emission tomography and NaF-positron-emission t

34 h lung immunopathology activity, measured by positron emission tomography, and tracked treatment resp

35 ntified by Cerenkov energy transfer imaging, positron-emission tomography, and fluorescence imaging.

36 in vivo electrophysiology, calcium imaging, positron emission tomography, behavioral efficacy testin

37 supported by cerebrospinal fluid or amyloid positron emission tomography biomarkers.

38 [(11)C]PBR28 Positron Emission Tomography brain imaging of the 18-kDa

39 ultaneous brain imaging with high-resolution positron emission tomography brain imaging.

40 Positron-emission tomography can quantify these processe

41 IC) for Fluorine-18 fluorodeoxyglucose (FDG) Positron Emission Tomography - Computed Tomography (PET-

42 F-Fluorodeoxyglucose (inflammation activity) positron emission tomography, computed tomography calciu

43 TLG) measured with [(18)F]fluorodeoxyglucose positron emission tomography-computed tomography ((18)F-

44 e accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FD

45 ty of multicancer blood testing coupled with positron emission tomography-computed tomography (PET-CT

46 vity (TGA) on [18]F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT

47 ted these functions in mice and humans using positron emission tomography-computed tomography (PET/CT

48 ctable levels of infection, as determined by positron emission tomography-computed tomography imaging

49 central location, adenocarcinoma, and higher positron emission tomography-computed tomography nodal s

50 was to evaluate the activity of FAP via FAPI-positron emission tomography-computed tomography scans i

51 FAPI-positron emission tomography-computed tomography scans o

52 FAPI-positron emission tomography-computed tomography scans r

53 (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-

54 by means of [(18)F]fluoro-2-deoxy-d-glucose Positron Emission Tomography/Computed Tomography ((18)F-

55 assess the role of (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography ((18)FD

56 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FD

57 Myocardial perfusion imaging, including positron emission tomography/computed tomography (PET/CT

58 onance imaging, and (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography (PET/CT

59 in quantitative (18)F-sodium fluoride (NaF) positron emission tomography/computed tomography (PET/CT

60 enously injected into the mice and imaged by positron emission tomography/computed tomography (PET/CT

61 Fluorodeoxyglucose (F-FDG) positron emission tomography/computed tomography (PET/CT

62 the value of (18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT

63 ve total bone imaging (QTBI) using (18)F-NaF positron emission tomography/computed tomography (PET/CT

64 Patients who achieved a complete response by positron emission tomography/computed tomography at thei

65 Dynamic positron emission tomography/computed tomography imaging

66 onium-89-oxine-labeled eosinophils by serial positron emission tomography/computed tomography imaging

67 volume (1000 islets) could be visualized by positron emission tomography/computed tomography imaging

68 Fluorodeoxyglucose positron emission tomography/computed tomography imaging

69 nflammation using (18)F-2-fluorodeoxyglucose-positron emission tomography/computed tomography imaging

70 Patients underwent a 3-month post-CRT positron emission tomography/computed tomography scan an

71 on days 1 and 15, followed by an exploratory positron emission tomography/computed tomography scan.

72 ximab-AVD for 4 to 6 cycles based on interim positron emission tomography/computed tomography scannin

73 ts: The median (range) lung cavity volume on positron emission tomography/computed tomography scans w

74 TMTV was computed on baseline positron emission tomography/computed tomography using t

75 [(18)F]Fluorodeoxyglucose positron emission tomography/computed tomography was per

76 [F] fluoro-D-glucose positron emission tomography/computed tomography was use

77 y mass (SULmax) on [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography would p

78 d metabolic activity in the arterial wall on positron emission tomography/computed tomography, indica

79 low reserve (MFR) measured by cardiac (82)Rb-positron emission tomography/computed tomography.

80 dividuals underwent (18)F-fluorodeoxyglucose positron emission tomography/computed tomography; AmygA,

81 d for 22 patients after whole-body CT during Positron Emission Tomography-CT.

82 %, 80%, and 91% for (18)F-fluorodeoxyglucose positron emission tomography/CT and 60%, 100%, 100%, and

83 (18)F-Fluorodeoxyglucose positron emission tomography/CT and white blood cell sin

84 In contrast, biodistribution and positron emission tomography demonstrated strong myocard

85 Longitudinal amyloid small animal positron emission tomography demonstrates accelerated am

86 years of clinical follow-up and with amyloid positron emission tomography, diffusion tensor imaging,

87 Patients undergoing cardiac stress positron emission tomography, echocardiogram, and renal

88 ng been utilized in fluorodeoxyglucose-based positron emission tomography (FDG-PET) as a contrast mec

89 homa, we conducted serial fluorodeoxyglucose positron emission tomography (FDG-PET) at baseline, afte

90 criteria with respect to fluorodeoxyglucose positron emission tomography (FDG-PET) response criteria

91 s underwent brain [(18)F]-fluorodeoxyglucose positron emission tomography (FDG-PET) scans.

92 ars old underwent baseline [(11)C]raclopride positron emission tomography followed by open L-DOPA for

93 MRI and positron emission tomography have shown that neurodegene

94 Coronary (18)F-fluoride positron emission tomography identifies ruptured and hig

95 Gating of positron emission tomography images has been shown to re

96 and [(67)Cu]Cu-MeCOSar-Tz revealed that the positron emission tomography images produced by the form

97 tion of prostate cancer by near-infrared and positron emission tomography imaging after systemic admi

98 orophores to detect myeloid cells by in vivo positron emission tomography imaging and optical modalit

99 Noninvasive positron emission tomography imaging clearly reveals tha

100 protein in brain and lungs using functional positron emission tomography imaging in vivo.

101 Positron emission tomography imaging of the (64)Cu-label

102 tressors in conjunction with high resolution positron emission tomography imaging of the brain.

103 -HT modified NPs is confirmed by noninvasive positron emission tomography imaging studies.

104 on clinical profile, 18F-fluorodeoxyglucose-positron emission tomography imaging, cardiac magnetic r

105 ctreotide[Trp(2-CF(2)(18)F)] enables in vivo positron emission tomography imaging.

106 Bq(124)I-omburtamab was used for radioimmuno-positron emission tomography imaging.

107 oding and amyloid-beta accumulation with PiB-positron emission tomography imaging.

108 To date, positron-emission tomography imaging remains the gold st

109 structural brain measures using [(11)C]UCB-J positron emission tomography in 18 patients with schizop

110 ctional magnetic resonance imaging and D2/3R positron emission tomography in 51 healthy volunteers, t

111 using the whole-brain analysis technique of positron emission tomography in male mice.

112 an papillomavirus-specific CD8(+) T cells by positron emission tomography in mice bearing human papil

113 We used positron emission tomography in rats to quantify regiona

114 CCR2 positron emission tomography is a promising new biomarke

115 rganoid and cell cultures as well as in vivo positron emission tomography-magnetic resonance imaging

116 hybrid (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/magnetic resonance imaging

117 We used simultaneously acquired (11) C-PBR28 positron emission tomography/magnetic resonance imaging

118 stribution volume (TSPO V(T)), measured with positron emission tomography, mainly reflects gliosis in

119 been shown to be accurate when compared with positron emission tomography MBF measured in the same pa

120 ange between pyruvate and lactate but not by positron emission tomography measurements of HK-II-media

121 ve regional genetic effects of voxelwise FDG-positron emission tomography measures between 116 ROIs a

122 ence, photoacoustic, magnetic resonance, and positron emission tomography modalities.

123 canning on a simultaneous magnetic resonance-positron emission tomography (MR-PET) scanner with the s

124 ncreased BAT volume and activity measured by positron emission tomography-MRI.

125 0 mg/kg) or saline and then received in vivo positron emission tomography of striatal dopamine synthe

126 On baseline positron emission tomography, patients in the top Lp(a)

127 ts who had a clinical evaluation and amyloid positron emission tomography (PET) (A), tau PET (T), and

128 inical risk stratification in the context of positron emission tomography (PET) -adapted treatment is

129 elds, especially that of an important cancer positron emission tomography (PET) agent [(18)F]5-fluoro

130 e investigate the potential of (18)F-mFBG, a positron emission tomography (PET) analogue of the (123)

131 sing fMRI and brain glucose metabolism using positron emission tomography (PET) and (18)F-fluorodeoxy

132 n mGluR5 availability in MTLE patients using positron emission tomography (PET) and [(11) C]ABP688, a

133 urteen participants were scanned twice using positron emission tomography (PET) and [(11)C]carfentani

134 Positron emission tomography (PET) and [(11)C]UCB-J, a r

135 Fluorodeoxyglucose (FDG) positron emission tomography (PET) and cardiac magnetic

136 (11)C]rifampin (administered as a microdose) positron emission tomography (PET) and computed tomograp

137 ardized uptake value (SUVmax) at baseline on positron emission tomography (PET) and HT risk.

138 ivo at the subfield level using simultaneous positron emission tomography (PET) and magnetic resonanc

139 Two longitudinal flortaucipir (FTP) positron emission tomography (PET) and magnetic resonanc

140 We combined [(11)C]PK11195 positron emission tomography (PET) and resting-state fun

141 Positron emission tomography (PET) and single-photon ima

142 Using positron emission tomography (PET) and the [(18)F]AV1451

143 Here, we provide a brief overview of positron emission tomography (PET) applications that cou

144 ce imaging (MRI) and (64)Cu-DOTA-trastuzumab positron emission tomography (PET) are used to estimate

145 y naltrexone measured with [(11)C]-LY2795050 positron emission tomography (PET) as a predictor of res

146 (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography (PET) at baseline and 6 mon

147 Whilst cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers for amyloi

148 (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) can detect vascular i

149 18F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) combined with compute

150 Dosimetry models using preclinical positron emission tomography (PET) data are commonly emp

151 Cognitive and (18) F-florbetapir positron emission tomography (PET) data were compared in

152 Amyloid positron emission tomography (PET) detects amyloid plaqu

153 approved cerebrospinal fluid or amyloid beta positron emission tomography (PET) diagnostic tests.

154 nt chemical scaffolds in pharmaceuticals and positron emission tomography (PET) diagnostics.

155 and JHU37160, and the first dedicated (18)F positron emission tomography (PET) DREADD radiotracer, [

156 Positron emission tomography (PET) enables non-invasive

157 iffusion weighted imaging (DWI), and dynamic positron emission tomography (PET) for detection of meta

158 on emission computed tomography (SPECT), and positron emission tomography (PET) for ischemia diagnosi

159 measurement of receptor occupancy (RO) using positron emission tomography (PET) has been instrumental

160 ns between cerebral blood flow (CBF) and tau positron emission tomography (PET) images in independent

161 Aspiring to develop a positron emission tomography (PET) imaging agent for the

162 Herein, we report a (64)Cu positron emission tomography (PET) imaging agent that sh

163 We investigated whether positron emission tomography (PET) imaging allows identi

164 pecific for mHTT aggregates could serve as a positron emission tomography (PET) imaging biomarker for

165 Moreover, by employing (64)Cu(2+), positron emission tomography (PET) imaging can be achiev

166 Towards this end, positron emission tomography (PET) imaging has emerged a

167 In vivo positron emission tomography (PET) imaging is a key moda

168 s (13-15) have been synthetized as potential positron emission tomography (PET) imaging ligands for m

169 Positron emission tomography (PET) imaging of the 18 kDa

170 Past acetylcholinesterase positron emission tomography (PET) imaging studies impli

171 We selected subjects from a previous positron emission tomography (PET) imaging study in epil

172 OPA) is a diagnostic radiopharmaceutical for positron emission tomography (PET) imaging that is used

173 e levels of mGlu5 receptor availability with positron emission tomography (PET) imaging using the mGl

174 We here use in vivo positron emission tomography (PET) imaging, flow cytomet

175 (FTP) and (11)C-Pittsburgh compound-B (PiB) positron emission tomography (PET) imaging, we measured

176 acking of Abeta accumulation with [(11)C]PiB positron emission tomography (PET) imaging.

177 , an activatable MPO activity radioprobe for positron emission tomography (PET) imaging.

178 s radiopharmaceuticals and (86)Y tracers for positron emission tomography (PET) imaging.

179 luorides are widely used as radiotracers for positron emission tomography (PET) imaging.

180 vivo neuroinflammation using [(11)C]PK11195 positron emission tomography (PET) imaging.

181 ring probe [C-11]-(+)-PHNO was measured with positron emission tomography (PET) in 79 human subjects

182 Positron emission tomography (PET) is a diagnostic nucle

183 Positron emission tomography (PET) is a molecular imagin

184 Radiomics using 18-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising approa

185 Positron emission tomography (PET) is an important imagi

186 Arterial (18)fluorodeoxyglucose (FDG) positron emission tomography (PET) is considered a measu

187 The availability of a MAGL-specific positron emission tomography (PET) ligand would consider

188 ed tomography (CT) compared with rubidium-82 positron emission tomography (PET) MBF estimates in a hi

189 Here, we create a non-invasive positron emission tomography (PET) methodology to track

190 Fluorine-18 flurpiridaz is a novel positron emission tomography (PET) myocardial perfusion

191 panel of radiochemicals has enabled in vivo positron emission tomography (PET) of tau pathologies in

192 Positron emission tomography (PET) plays key roles in dr

193 Coronary (18)F-sodium fluoride ((18)F-NaF) positron emission tomography (PET) provides an assessmen

194 Positron emission tomography (PET) provides quantitative

195 ated analogue of the previously reported CB2 positron emission tomography (PET) radioligand [(11)C]RS

196 relates minute-by-minute fluctuations of the positron emission tomography (PET) radioligand [11C]racl

197 [(11)C]carfentanil, a selective MOR agonist positron emission tomography (PET) radioligand, to inves

198 Positron emission tomography (PET) radioligands (radioac

199 scribes the radiolabeling of biotin with the positron emission tomography (PET) radionuclide carbon-1

200 ng cancer in vivo using a voltage-sensitive, positron emission tomography (PET) radiotracer known as

201 nd-of-treatment (EOT) 18F-fluorodeoxyglucose positron emission tomography (PET) scan to guide consoli

202 with CSF P-tau181 and predicted positive Tau positron emission tomography (PET) scans (area under the

203 All subjects underwent positron emission tomography (PET) scans with two differ

204 ive features for AD classification using tau positron emission tomography (PET) scans.

205 We examined (18) F-Flortaucipir (FTP)-positron emission tomography (PET) signal across 41 cort

206 logy and treatment of anxiety disorders, but positron emission tomography (PET) studies probing the t

207 In the current positron emission tomography (PET) study, we evaluated t

208 217 shows stronger correlations with the tau positron emission tomography (PET) tracer [(18)F]flortau

209 (18)F-PI-2620 is a positron emission tomography (PET) tracer with high bind

210 Recent advances in positron emission tomography (PET) tracers now enable in

211 Positron emission tomography (PET) tracers that bind to

212 (68)Ga-DOTA-Tyr3-octreotide ((68)Ga-DOTATOC) positron emission tomography (PET) tumor uptake and volu

213 Positron emission tomography (PET) uses radiotracers to

214 Background Positron emission tomography (PET) using (18)F-sodium fl

215 ication-free participants with MDD underwent positron emission tomography (PET) using [(11)C]CUMI-101

216 tandard (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) viability.

217 dardized uptake value ratios (SUVRs) for tau positron emission tomography (PET) were compared among 1

218 MRI data and a subset (n = 90) with amyloid positron emission tomography (PET) were included.

219 [(11)C]NOP-1A and positron emission tomography (PET) were used to measure

220 riatal D(2) receptor binding (examined using positron emission tomography (PET) with (11)C-raclopride

221 e present study was to validate and optimize positron emission tomography (PET) with (11)C-vorozole f

222 lopment of radioligands for Y(1)R imaging by positron emission tomography (PET) with a special emphas

223 ment after several antibiotic therapiesand a positron emission tomography (PET) with hypercaptation s

224 ds that enable tracking brain amyloid or tau positron emission tomography (PET) with magnetic resonan

225 gh compound B) and tau ((18) F-flortaucipir) positron emission tomography (PET) with prospective neur

226 aromatase availability in the amygdala using positron emission tomography (PET) with the aromatase in

227 quantified DA D1 receptor availability using positron emission tomography (PET) with the radioligand

228 Here, we used positron emission tomography (PET) with the SV2A radioli

229 eta ((18)F-florbetapir or (18)F-florbetaben) positron emission tomography (PET), (18)F-flortaucipir P

230 respectively, were 0.91 and 0.92 for amyloid positron emission tomography (PET), 0.89 and 0.74 for (1

231 tion across the brain of older adults, using positron emission tomography (PET), and investigate how

232 (KOR) availability in the human brain using positron emission tomography (PET), before and after a c

233 mine release at rest using [(11)C]raclopride positron emission tomography (PET), functional connectiv

234 t baseline (18)F-sodium fluoride ((18)F-NaF) positron emission tomography (PET), repeat computed tomo

235 These techniques include positron emission tomography (PET), single-photon emissi

236 In positron emission tomography (PET), the finite range ove

237 Positron emission tomography (PET), traditionally used i

238 We used noninvasive immuno-positron emission tomography (PET), using (89)Zr-labeled

239 (18)F]-fluoro-l-phenylalanine ([(18)F]-DOPA) positron emission tomography (PET), we compared dopamine

240 Using positron emission tomography (PET), we explored the asso

241 Using positron emission tomography (PET), we identified the do

242 hors sought to assess whether (18)F-fluoride positron emission tomography (PET)-computed tomography (

243 The relationship among positron emission tomography (PET)-derived extent of isc

244 On the basis of promising results of positron emission tomography (PET)-directed treatment ap

245 (18)F-PI-2620 is a next generation tau positron emission tomography (PET)-tracer that has demon

246 ides can be used for diagnostic imaging with positron emission tomography (PET).

247 florbetaben (FBB) and 18F-flutemetamol (FMM) positron emission tomography (PET).

248 utoradiography, ex vivo biodistribution, and positron emission tomography (PET).

249 d at developing a tracer for imaging CD80 by positron emission tomography (PET).

250 eased morbidity and mortality.(18)F-fluoride positron emission tomography (PET)/computed tomography (

251 rmine the negative predictive value (NPV) of positron emission tomography (PET)/computed tomography (

252 (11)C-palmitate and (18)F-fluorodeoxyglucose positron emission tomography (PET)/computed tomography (

253 (18)F-Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (

254 n this study, we sought to develop a bimodal positron emission tomography (PET)/fluorescent imaging a

255 All received an (18)F-DOPA positron emission tomography (PET)/magnetic resonance (M

256 received an integrated (i.e., simultaneous) positron emission tomography (PET)/magnetic resonance im

257 We used flortaucipir positron-emission tomography (PET) and florbetapir PET t

258 We previously showed separation of the positron-emission tomography (PET) imaging tracer 3'-deo

259 lves diagnostic procedures, which use either positron-emission tomography (PET) or single-photon imag

260 -MRI) near-infrared spectroscopy (NIRS), and positron-emission tomography (PET).

261 Imaging measures of AT(N) (amyloid and tau positron emission tomography [PET]) structural magnetic

262 athology (determined using neuropathology or positron emission tomography [PET]).

263 [MRI]) and/or next-generation imaging (NGI), positron emission tomography [PET], PET/CT, PET/MRI, or

264 Participants underwent Pittsburgh Compound B Positron Emission Tomography (PiB-PET) to assess fibrill

265 chemosensitive to salvage therapy with: (1) positron emission tomography-positive disease or (2) bon

266 report the small molecule, allysine-binding positron emission tomography probe, (68)Ga-NODAGA-indole

267 tomography, magnetic resonance imaging, and positron emission tomography provides important insights

268 underwent structural MRI, (18)F-florbetapir positron emission tomography, pure tone audiometry and c

269 nt model and human tissues, using a targeted positron emission tomography radiotracer ((64)Cu-DOTA-EC

270 synthesized and tested the performance of a positron emission tomography radiotracer ((68)Ga-DOTA [1

271 Positron emission tomography revealed that DCZ selective

272 ng procedure can be compressed into a single positron emission tomography scan session lasting less t

273 pressive disorder underwent one [(18)F]FEPPA positron emission tomography scan to measure PFC and ACC

274 Positive positron emission tomography scan was seen in 51% (55/10

275 f laboratory testing, 18F-fluorodeoxyglucose positron emission tomography scan, cardiac magnetic reso

276 d tomography (CT)/magnetic resonance imaging/positron emission tomography scans and at least 10% resp

277 is and activity on [(18)F]fluorodeoxyglucose positron emission tomography scans did not correlate wit

278 y control subjects completed high-resolution positron emission tomography scans with the novel FAAH r

279 In 4 DSP cases with 18F-fluorodeoxyglucose positron emission tomography scans, acute LV myocardial

280 compounds described herein are applicable in positron emission tomography, single-photon emission com

281 ally inoperable patients with biopsy-proven, positron emission tomography-staged T1 to 2 (<= 5 cm) N0

282 Positron emission tomography studies have demonstrated l

283 Preclinical and human positron emission tomography studies have produced incon

284 We performed [(18) F]-fluorodopa positron emission tomography studies of 57 homozygous an

285 This was confirmed in rat and monkey positron emission tomography studies using [(18)F]9.

286 rospective [(18)F]-dihydroxyphenyl-L-alanine positron emission tomography study in antipsychotic naiv

287 We employed positron emission tomography to measure both dopamine re

288 of drug use or pre-existing traits, we used positron emission tomography to measure mGlu5 receptor a

289 Here we used positron emission tomography to show that MOR levels in

290 1-M) after exposure, echocardiography, micro-positron emission tomography(u-PET), collagen quantifica

291 [(11)C]NOP-1A positron emission tomography was used to measure the bin

292 [(11)C]FLB 457 and positron emission tomography were used to measure D(2/3)

293 D(2)RO was determined using positron emission tomography with (11)C-raclopride as th

294 ingulate cortex, and prefrontal cortex using positron emission tomography with [(11)C]LY2795050.

295 abolism measured by (18)F-fluorodeoxyglucose positron emission tomography with and without improved s

296 We hypothesized that F-fluorodeoxyglucose positron emission tomography with computed tomography (F

297 F-fluorodeoxyglucose positron emission tomography with CT may noninvasively d

298 DFA metabolism and organ partitioning using positron emission tomography with oral and intravenous l

299 robabilistic reversal learning task and used positron emission tomography with the [(11)C]-(+)-PHNO a

300 ttern of annihilation photons detected using positron emission tomography, with respect to anatomical